GLP-1 Weight-Loss Medications Pose Risks to Unborn Babies Due to Contraceptive Non-Use

Strategic Insights -

Women aged 18-49 prescribed GLP-1 receptor agonists for weight loss often don't use effective birth control, despite documented risks if pregnancy occurs. Researchers analyzed health records of over 1.6 million women and found that only 21% of those prescribed GLP-1 medications reported contraceptive use. The study highlights the need for clearer guidelines on prescribing these medications to women of childbearing age.

Key Takeaways:

  • Over 1.6 million women's health records were analyzed, revealing a significant number of women prescribed GLP-1 receptor agonists did not use effective birth control.
  • Only 21% of women who started GLP-1 treatment reported contraceptive use, despite the documented risks of pregnancy.
  • Associate Professor Luke Grzeskowiak noted that in 2022 alone, over 6,000 women started GLP-1 treatment, with over 90% not having a diabetes diagnosis.
  • The study found that 2.2% of women became pregnant within six months of beginning GLP-1 treatment, with higher rates among younger women and those without diabetes.
  • Women diagnosed with polycystic ovary syndrome were twice as likely to become pregnant, possibly due to improved fertility linked to weight loss.
  • Animal studies have associated GLP-1 exposure during pregnancy with reduced fetal growth and skeletal deformities, although human data remains limited.
  • The UK advises women using GLP-1 receptor agonists to avoid pregnancy and use reliable contraception, a recommendation not consistently applied in Australian clinical settings.

Statistics:

  • 21% of women who started GLP-1 treatment reported contraceptive use.
  • 2.2% of women became pregnant within six months of beginning GLP-1 treatment.
  • Over 6,000 women started GLP-1 treatment in 2022, with over 90% not having a diabetes diagnosis.
  • 90% of women who started GLP-1 treatment in 2022 did not have a diabetes diagnosis.
  • 2.2% is the percentage of women who became pregnant within six months of beginning GLP-1 treatment.

Sources:

  • Incidence of GLP-1 receptor agonist use by women of reproductive age attending general practices in Australia, 2011-2022: a retrospective open cohort study (https://onlinelibrary.wiley.com/doi/10.5694/mja2.70026)